Navigation Links
Strategic Initiatives, Executive Transitions, and Strengthened Portfolios to Increase Shareholder Value - Research Report on Trius, HCA, Alere, UHS, and Bio-Reference
Date:8/5/2013

NEW YORK, August 5, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Trius Therapeutics, Inc. (NASDAQ: TSRX), HCA Holdings, Inc. (NYSE: HCA), Alere Inc. (NYSE: ALR), Universal Health Services Inc. (NYSE: UHS), and Bio-Reference Laboratories Inc. (NASDAQ: BRLI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Trius Therapeutics, Inc. Research Report

On July 30, 2013, Trius Therapeutics Inc. (Trius) and Cubist Pharmaceuticals Inc. (Cubist) jointly announced a definitive agreement under which Cubist will acquire all outstanding shares of Trius for $13.50 per share in cash or nearly $707 million on a fully diluted basis. Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius, said, "This transaction culminates years of intense work by the Trius team to achieve this outcome, and our shareholders are being rewarded for their involvement and support of the company." According to the Companies, the agreement includes each Trius stockholder to receive one Contingent Value Right (CVR), entitling the holder to receive an additional cash payment of up to $2.00 for each share they own if certain commercial sales milestones are achieved. The Full Research Report on Trius Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [

SOURCE Investors' Reports
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Emergent and DiFusion Form Strategic Partnership to Take CleanFuze™ Antimicrobial Implants to Market
2. GlycoVaxyn AG secures CHF 5.1 million Strategic Translation Award from the Wellcome Trust to finance clinical development of Shigella vaccine
3. DuPont Realigns Leadership Team to Accelerate Integrated Science Execution, Explores Strategic Alternatives for Performance Chemicals
4. Pittsburgh Life Sciences Greenhouse Makes Strategic Adjustment To Put Laser Focus On 2013 Goals
5. Alpha Source, Inc. Hires Strategic Sourcing Manager
6. BioLife Solutions Announces Strategic Partnership with HemaCare
7. Paul Knittle Joins Wireless Analytics as Director of Strategic Accounts
8. Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc.
9. Elsevier Signs Strategic Collaboration Agreement with Peoples Medical Publishing House, China
10. VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials
11. Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... PORTLAND, Oregon , August 4, 2015 /PRNewswire/ ... published by Allied Market Research, titled, "World Cardiac ... global cardiac biomarker market would generate the revenue ... of 18.9% from 2015 to 2020. Cardiac Troponins ... throughout the forecast period due to high sensitivity ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... diagnostic tests – today announced that Robert A. Gregg, PhD, has joined RPS ... than 30 years of relevant experience and remarkable achievements in the medical device ...
(Date:8/4/2015)... Aug. 4, 2015  Blueprint Medicines (NASDAQ: BPMC ... kinase drugs for genomically defined diseases, today announced that ... a company overview at the 2015 Wedbush PacGrow Healthcare ... EDT. A live webcast of the event ... the Blueprint Medicines website at www.blueprintmedicines.com . An ...
(Date:8/4/2015)... Francisco, CA (PRWEB) , ... August 04, 2015 , ... ... difference by inviting a diverse selection of entrepreneurs from across the United States to ... CEO Jessica Richman is honored to be chosen to be among the attendees. , ...
Breaking Biology Technology:Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 2Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 3Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 4Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 5RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 2RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 3White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2
... Electronic health record systems generally are perceived to have ... more clinics consider moving from paper charts to EHR ... barriers to entry. , ,The evolution of systems for ... robust data security has prompted more hospitals and ...
... - Just six weeks after taking the helm at ... to pursue opportunities in the private sector, the organization announced. ... has served as general counsel to WiCell's parent, the ... high-tech and biotechnology industries. , ,Donley, who joined WARF in ...
... An education research team at the University of Wisconsin-Madison ... to study the impact of digital media on youth ... investment will support 24 national studies of different aspects of ... , ,"What MacArthur is actually trying to do, with this ...
Cached Biology Technology:GE Healthcare launches hybrid electronic record 2Donley resigns as WiCell director 2UW gets $3M to explore educational gaming 2UW gets $3M to explore educational gaming 3
(Date:7/21/2015)... , July 21, 2015 Passwords have ... seen in the recent U.S. Office of Personnel ... to the infosec conundrum, but developers and end-users ... To address this dilemma, Biometrics-as-a-Service provider HYPR Corp. ... Tokenization SDK for third party integration. ...
(Date:7/9/2015)... , July 07, 2015 ... announced the addition of the "Biometrics for ... Forecasts 2015-2020" report to their offering. ... major contributor to this growth and the forecast ... billion in revenue for companies involved in delivering ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... a form of breast cancer known as estrogen receptor positive ... the treatment and prevention of recurring breast cancer. Currently, ... dose is prescribed for every patient. New research at ... patient-specific genetic factors, lack of exposure to vitamin D during ...
... DNA code for a complex region of the human genome ... Fraser University, chart new territory in immunity research. , They ... how well they operate and, potentially, what they fight off, ... drugs, treatments and vaccinations are designed to treat whole populations ...
... the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan ... study of seven missense variants of the BRCA1 gene ... to the risk of suffering breast or ovarian cancer. ... PLoS One The classification of these three ...
Cached Biology News:Cold winters freezing out breast cancer treatment 2Scientists find ethnicity linked to antibodies 2Identified as responsible for breast and ovarian hereditary cancer 3 mutations at BRCA1 gene 2
...
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
...
Water Distilled (Gibco™) is membrane filtered and endotoxin screened....
Biology Products: